Verrica Pharmaceuticals Achieves Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with Common Warts - GlobeNewswire

Verrica Pharmaceuticals Achieves Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with Common Warts  GlobeNewswire

51% of subjects in Cohort 2 achieved complete clearance of all treatable warts. VP-102 was well-tolerated with no serious adverse events reported. Common ...